Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
2010 · Molecular Cancer Therapeutics · 336 citations
https://doi.org/10.1158/1535-7163.mct-09-1171
B
Brigid C. Browne
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
86
Papers
1.3K
Citations
16
h-index
16
i10-index
Brigid C. Browne is an academic researcher from Garvan Institute of Medical Research. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 16, co-authored 74 publications.
Papers by this author
worksInhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
2010 · Annals of Oncology · 98 citations
https://doi.org/10.1093/annonc/mdq349
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
2014 · Molecular Cancer · 42 citations
https://doi.org/10.1186/1476-4598-13-157
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells
2017 · International Journal of Oncology · 41 citations
https://doi.org/10.3892/ijo.2017.3976
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
2012 · Breast Cancer Research and Treatment · 37 citations
https://doi.org/10.1007/s10549-012-2260-9
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
2018 · Investigational New Drugs · 29 citations
https://doi.org/10.1007/s10637-018-0649-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat